Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001085146-24-001438)

Filing Details

Accession Number:: 0001085146-24-001438
Form Type:: 13G Filing
Publication Date:: 2024-02-13 19:00:00

Filed By:: 683 Capital Partners
Company:: Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR)
Filing Date:: 2024-02-14
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
683 Capital Management	70,000	70,000	70,000	4.7%
683 Capital Partners	70,000	70,000	70,000	4.7%
Ari Zweiman	70,000	70,000	70,000	4.7%

Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 6)*

Eiger BioPharmaceuticals, Inc.

(Name of Issuer)

Common stock, $0.001 par value per share

(Title of Class of Securities)

28249U105

(CUSIP Number)

December 31, 2023

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[ ] Rule 13d-1(b)

[X] Rule 13d-1(c)

[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).

CUSIP No.: 28249U105


1	NAME OF REPORTING PERSON 683 Capital Partners, LP I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ]
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER 0
		6	SHARED VOTING POWER 70,000
		7	SOLE DISPOSITIVE POWER 0
		8	SHARED DISPOSITIVE POWER 70,000
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 70,000
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.7%
12	TYPE OF REPORTING PERSON PN
On January 8, 2024, the Issuer effected a 1-30 reverse stock split of its common stock (the Reverse Stock Split). The amount of securities reported on this Schedule 13G/A has been adjusted to reflect the Reverse Stock Split.

CUSIP No.: 28249U105

ITEM 1(a).	NAME OF ISSUER: Eiger BioPharmaceuticals, Inc.
ITEM 1(b).	ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 2155 Park Boulevard, Palo Alto, California 94306
ITEM 2(a).	NAME OF PERSON FILING: 683 Capital Management, LLC 683 Capital Partners, LP Ari Zweiman
ITEM 2(b).	ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, NY 10019.
ITEM 2(c).	CITIZENSHIP: 683 Capital Management, LLC is a Delaware limited liability company. 683 Capital Partners, LP is a Delaware limited partnership. Ari Zweiman is a citizen of the United States.
ITEM 2(d).	TITLE OF CLASS OF SECURITIES: Common stock, $0.001 par value per share (the Common Stock).
ITEM 2(e).	CUSIP NUMBER: 28249U105
ITEM 3.	IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
	(a) [ ]	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
	(b) [ ]	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
	(c) [ ]	Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
	(d) [ ]	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
	(e) [ ]	An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
	(f) [ ]	An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
	(g) [ ]	A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
	(h) [ ]	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i) [ ]	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j) [ ]	A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
	(k) [ ]	Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:

ITEM 4.	OWNERSHIP

	(a) Amount beneficially owned:
	As of December 31, 2023, 683 Capital Partners, LP beneficially owned 70,000 shares of Common Stock. 683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the 70,000 shares of Common Stock beneficially owned by 683 Capital Partners, LP. Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially owned the 70,000 shares of Common Stock beneficially owned by 683 Capital Management, LLC. On January 8, 2024, the Issuer effected a 1-30 reverse stock split of its common stock (the Reverse Stock Split). The amount of securities reported on this Schedule 13G/A has been adjusted to reflect the Reverse Stock Split.
	(b) Percent of class:
	The following percentage is based on 44,384,684 shares of Common Stock outstanding as of November 6, 2023, as disclosed in the Issuers Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023. On January 8, 2024, the Issuer effected a 1-30 reverse stock split of its common stock (the Reverse Stock Split). The amount of securities reported on this Schedule 13G/A has been adjusted to reflect the Reverse Stock Split. As of December 31, 2023, each of the Reporting Persons may be deemed to have beneficially owned approximately 4.7% of the outstanding shares of Common Stock.
	(c) Number of shares as to which the person has:
	(i) sole power to vote or to direct the vote:
	See Cover Pages Items 5-9.
	(ii) shared power to vote or to direct the vote:
	See Cover Pages Items 5-9.
	(iii) sole power to dispose or direct the disposition of:
	See Cover Pages Items 5-9.
	(iv) shared power to dispose or to direct the disposition of:
	See Cover Pages Items 5-9.
ITEM 5.	OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
ITEM 6.	OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: Not applicable.
ITEM 7.	IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY: Not applicable.
ITEM 8.	IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: See Exhibit A to the Schedule 13G filed with the SEC on October 15, 2018.
ITEM 9.	NOTICE OF DISSOLUTION OF GROUP: Not applicable.
ITEM 10.	CERTIFICATION: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.